2021
DOI: 10.1093/cid/ciab641
|View full text |Cite
|
Sign up to set email alerts
|

Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children

Abstract: Background Moxifloxacin is a priority recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics, QT-interval prolongation and evaluate optimal dosing in children with RR-TB. Methods Pharmacokinetic data were pooled from two observational studies in South African c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
16
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 18 publications
(17 citation statements)
references
References 41 publications
(51 reference statements)
1
16
0
Order By: Relevance
“…Higher maximum doses have been utilized when there is low-level resistance, such as in the presence of a 90Val gyrA mutation that is typically associated with an moxifloxacin MIC of < 1, though the efficacy of this approach has recently been questioned [45] . The maximum dose for moxifloxacin is 15 mg/kg daily capped at 600–800 mg per dose and for levofloxacin is 20 mg/kg daily capped at 1250–1500 mg per day [48] , [49] , [50] . Modeling studies suggest that current dose bands may result in lower drug exposure in children and doses > 20 mg/kg daily may be more optimal [51] , [52] .…”
Section: Therapeutics For Pediatric Mdr-tbmentioning
confidence: 99%
“…Higher maximum doses have been utilized when there is low-level resistance, such as in the presence of a 90Val gyrA mutation that is typically associated with an moxifloxacin MIC of < 1, though the efficacy of this approach has recently been questioned [45] . The maximum dose for moxifloxacin is 15 mg/kg daily capped at 600–800 mg per dose and for levofloxacin is 20 mg/kg daily capped at 1250–1500 mg per day [48] , [49] , [50] . Modeling studies suggest that current dose bands may result in lower drug exposure in children and doses > 20 mg/kg daily may be more optimal [51] , [52] .…”
Section: Therapeutics For Pediatric Mdr-tbmentioning
confidence: 99%
“…Drug-resistant-TB in children has traditionally required treatment for up to 18 months, using drug regimens with high pill burdens and suboptimal side effect profiles. Recent progress in the treatment of drug-resistant-TB in adults and accumulation of safety and pharmacokinetic data from paediatric studies have meant that shorter, safer and more tolerable drug-resistant-TB treatment regimens for children are now being recommended and implemented globally [53 ▪ ,54 ▪ ,55,56 ▪ ,57].…”
Section: Tuberculosis Treatment For Childrenmentioning
confidence: 99%
“…In a prospective observational study of 70 children receiving treatment for RR-TB disease with levofloxacin-based regimens, 41 children had ECG data available and none had QTcF >450 msec recorded over the 2 hours post-treatment administration. 4 A mean change in QTcF of 4.7 ms was recorded; 5 (13%) children had QTcF change 30–60 ms and 1 had a change >60 ms. Only 1 child received another QT-prolonging drug, clofazimine, and they had a QTcF change of 44 ms. 4 Across 2 observational studies where 85 children received moxifloxacin (mean dose 11 mg/kg/day) within treatment regimens for RR-TB, 5 children had a QTcF ≥450 to <500 ms (4 of 5 were receiving clofazimine), but no child had QTcF >500 ms. 5 As moxifloxacin has a short half-life, the maximum QT effects would be expected within a few days of starting treatment.…”
Section: Current Knowledge On Qt Interval Prolongation With Second-li...mentioning
confidence: 99%